Application of novel oral anticoagulants for the antithrombotic effect of cardiovascular system diseases
Abstract
Long-term oral anticoagulant is one of the methods for the treatment of cardiovascular system diseases, and the most widely used anticoagulant drug is warfarin, but its clinical application has been greatly limited due to its slow onset, easy to affect by various factors, and difficult dose control. In recent years, with the continuous in-depth research on cardiovascular system diseases, the emergence of new oral anticoagulants (NOAC) has greatly impacted the status of traditional anticoagulant warfarin because of its safety, stability and convenience of consumption. The purpose of this article is to review the classification and application of novel oral anticoagulants.
References
[1] Thomas, Wilke, Antje, et al. Persistence with VKA treatment in newly treated atrial fibrillation patients: an analysis based on a large
sample of 38,076 German patients.[J]. European Journal of Clinical Pharmacology, 2017.
[2] Simone, Stehle, Julia, et al. Pharmacogenetics of Oral Anticoagulants[J]. Clinical Pharmacokinetics, 2008.
[3] Chatterjee S , Sharma A , Uchino K , et al. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial
sequential analysis of randomized clinical trials.[J]. Coron Artery Dis, 2013, 24(8).
[4] Brinkmeier-Theofanopoulou M , Tzamalis P , Wehrkamp-Richter S , et al. Periprocedural anticoagulation during left atrial ab_x005flation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants[J]. Bmc Cardiovascular Disorders, 2018,
18(1):71.
[5] Stangier D J , Hildegard Sthle, Rathgen D K , et al. Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment[J]. The Journal of Clinical Pharmacology, 2008.
[6] Samama M M . The mechanism of action of rivaroxaban - An oral, direct Factor Xa inhibitor - Compared with other anticoagulants[J]. Thrombosis Research, 2010, 127(6):497-504.
[7] Reinhold, Kreutz. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.[J]. Current Clinical
Pharmacology, 2014.
[8] Kreutz R. Pharmacokinetics and pharmacodynamics of rivaroxaban–an oral, direct factor Xa inhibitor[J]. Current clinical pharmacology, 2014, 9(1): 75-83.
[9] Zhenxia, Zhang, Wang Jing The therapeutic effect of rivaroxaban on atrial fibrillation [J] Clinical Medical Research and Practice,
2018, 3 (32): 2
[10] Donglu, Zhang, Charles, et al. Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of
activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats.[J]. Drug metabolism and disposition: the biological fate of chemicals, 2013.
[11] Bounameaux H , Camm A J . Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor[J]. Drugs, 2014, 74(12):1455-
1455.
[12] Raskob G , Cohen A , Eriksson B , et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement[J]. Thromb Haemost, 2010, 104(09):642-649.
[13] Huisman, M. V , Lip, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties
in routine practice[J]. Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis, 2012, 107(5):838-
847.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.
